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Data envelopment analysis (DEA) is a widely used method in operations research for the benchmarking and 
empirical assessment of productive efficiency. We have previously applied DEA for treatment plan analysis and 
demonstrated its ability to determine relative plan quality, however considerations regarding the optimal use of 
DEA were not considered in that work. In the current work we have extended the complexity of the DEA 
modelling to include an increased number of measures of treatment plan quality as well investigating the best 
method of accounting for patient geometry.  Forty-one IMRT prostate treatment plans were retrospectively 
analysed using an input-oriented variable returns to scale DEA method. The impacts of DEA weight restrictions 
were analysed with reference to the ability of DEA to differentiate plan performance at a level of clinical 
significance. Patient geometry significantly influences plan quality and alternative methods for considering 
geometry in the DEA model were investigated. In this work we identify how best to use DEA for the relative 




Data Envelopment Analysis (DEA) is a method for benchmarking organisations that constructs a 
‘best-practice frontier’ which is used as a comparator for non-best practice organisations. In this 
paper, radiotherapy treatment plans are used instead of organisations to determine relative plan quality 
as described in our previous work. In the following we first summarise this work and provide an 
introduction to DEA in the context of treatment planning. We then analyse forty-one treatment plans 
retrospectively to identify an appropriate DEA model that can be applied in a clinical context to 
ensure treatment plan quality. 
Previously we used a simple single input and single output model to show that the operations 
research method of data envelopment analysis (DEA) could be used to assess relative quality among 
prostate treatment plans (Lin et al 2013). In that work we demonstrated that DEA efficiency could be 
used to assess the relative quality of prostate radiotherapy treatment plans using a single input and 
output and considering patient geometry via rectum-planning target overlap. We further demonstrated 
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that replanning low DEA efficiency plans with the aim of increasing the DEA efficiency improved the 
clinical assessment of plan quality. This paper extends our previous work to multiple inputs whilst 
introducing more sophisticated models to address different levels of complexity among inputs and 
investigating different approaches to handling patient geometry. The improved understanding of the 
interrelationships between DEA inputs, outputs, patient geometry and plan quality is a prerequisite for 
expanding the role of DEA to other clinical sites and is the aim of this work. 
DEA is a widely used method in operations research and management science for assessing the 
performance of a set of decision-making units (DMUs). In DEA terminology, the DMU is an entity 
that is responsible for converting inputs into outputs and whose performance is being evaluated 
(Charnes et al 1978, Cooper et al 2011). In a loose economic interpretation, the inputs represent the 
cost we pay to produce outputs. The concept of DEA is directly applicable to the problem of assessing 
treatment plan quality in radiotherapy in which the doses to organs at risk (OARs) are considered as 
the cost we pay for delivering dose to the planning target volume (PTV). A DMU in this context is 
therefore a treatment plan. 
DEA is attractive for plan analysis for three reasons: Firstly DEA is data oriented where 
performance is based only on the observed data with minimal assumptions; secondly DEA performs 
peer evaluation by comparing treatment plans with respect to a best practice reference set defined by 
historical plans. In other words it is a method directed towards Pareto efficient frontier generation in 
contrast to some knowledge based treatment planning solutions that are based on statistical measures; 
and thirdly the data used for inputs and outputs do not have to be commensurable, i.e. do not have to 
have a common measure. Thus we can simultaneously use, for example, volume, dose, biological 
dose, ratios or any other relevant parameter as our inputs and outputs. 
DMUs are assessed based on their ability to convert a set of inputs into outputs. This ability is 
referred to as efficiency and measured as a ratio of weighted outputs and weighted inputs. Given a set 
of DMUs (in our case, treatment plans), DEA assesses the relative efficiency of each plan by 
comparing it to all other plans in the set and searching for evidence of potential improvements, i.e. 
whether some of the plan parameters, cast as DEA inputs and outputs, can be improved without 
worsening any of its other inputs or outputs. DEA maximises the efficiency rating of each plan by 
automatically adjusting the weighting of the inputs and outputs to make the plan under investigation 
appear most favourable. These weights are referred to throughout the paper as DEA input/output 
weights. If, even under this most favourable consideration, other plans have better efficiency, then the 
plan under investigation is inefficient. Otherwise, if there is no evidence for potential improvements, 
the plan is considered fully efficient. If potential improvements are identified then a target solution is 
determined based on those fully efficient plans (known as peers) that are most similar to the plan 
being evaluated. The method ensures that the resulting relative efficiency lies between 0 and 1, where 
1 is fully efficient. In the following we present three simple examples to illustrate the intuition 
underlying an application of DEA in the assessment of treatment plan quality.  
 
Example 1: Consider four treatment plans (plan A, B, C, D), each being a historical 78Gy IMRT 
prostate treatment plan that was delivered to treat a patient in the past. We also consider a fifth plan, 
plan N, which corresponds to a plan for a new patient that is under evaluation. In the simplest case, 
similar to what is described by Lin (2013), we consider only two metrics to assess plan quality: The 
metrics selected are PTV V95, the percentage of PTV volume receiving at least 95% of the prescribed 
dose and rectal generalised equivalent uniform dose (gEUD). Since the aim is to obtain plans with 
consistently high PTV V95 and low rectal gEUD, an input-oriented DEA model is chosen which 
seeks to minimise input (rectal gEUD) while maintaining output (PTV V95). Alternatively, an output-
oriented DEA model would seek to maximise output while maintaining input levels. Input-orientation 
is used in the examples, and justified later. Figure 1 shows rectal gEUD (horizontal axis) and PTV 
V95 (vertical axis) for the five plans under consideration. Plans A, C and D are DEA-efficient as, 
within the set of plans considered, there is no evidence that lower rectal gEUD can be achieved while 
maintaining the same level of PTV V95. The three DEA efficient plans define the Pareto efficient 
frontier shown as the solid piecewise linear line through plans D, A and C. Those plans have an 
output to input ratio superior to historical plan B which is not DEA-efficient. The new plan N is also 
not DEA efficient and  the DEA evaluation determines that it should be able to achieve a rectal gEUD 
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reduction of almost 3 Gy (53.95-56.91) as shown in point N* while keeping the same PTV V95 value 
(98.39). N* is called the target for plan N and the difference between the two is referred to as Radial 
Slack. Radial slack is utilised in this work in one of the methods for managing patient geometry and is 
described later in this paper. DEA also determines the peer plans for N to be A and D as they define 
the line segment on which target N* lies, and provides information on the relative influence of each 
peer plan in setting the target.  
In the example plans, A and D have a peer-weight of 0.34 and 0.66 respectively and the DEA 
results are shown in Table 1. The targets for plan N are determined by applying these peer-weights so 
that rectal gEUD equals 53.95 (0.34 ×  56.97 +  0.66 ×  52.39) and PTV V95 equals its actual 
measure 98.39 (0.34 ×  99.05 +  0.66 ×  98.05). Peer plans indicate what a plan (such as N) should 
be able to achieve and may also help a planner determine how this could be achieved by considering 
comparative, but better, plans determined by DEA. The DEA model employed here is a so-called 
variable returns to scale model which appropriately models trading off changes in inputs and outputs 
in radiotherapy planning. The alternative would be a constant returns to scale model which assumes 
there is a constant relationship between an increase of input and output. In Example 1 this would 
mean that a unit increase of rectal gEUD would always correspond to a constant increase of PTV 
V95. However, the relationship between rectal gEUD and PTV V95 varies in a complex manner and 
hence a variable returns to scale DEA model is used in the following examples and results. Example 2 
generalises the DEA concept to a case with two inputs.  
 
Example 2: In addition to the data used in Example 1 we now consider a second input, PTV dose max, 
the maximum dose to PTV, as discussed later. Example 2 also includes one additional plan, plan E. In 
Example 2 we also assume that PTV V95 values are identical for all plans. This assumption is not a 
DEA requirement, but is made to be able to illustrate the problem in the two input dimensions only. 
Figure 2 illustrates the two inputs for all six considered plans. DEA now evaluates plan efficiency as 
the ratio of weighted sum of outputs and weighted sum of inputs. The weights determined are those 
most favourable for the plan under consideration, taking into consideration all other plans. In 
radiotherapy planning this means that DEA makes no a priori assumption of the relative importance 
of one input or output over another. In other words a DEA model recognises that different trade-offs 
are made for different patients. Table 2 shows an example where three different sets of weights are 
applied to the plan data. For weights 𝑤1 = 0.0 and 𝑤2 = 1.0, plan A is found to be DEA efficient; for 
weights 𝑤1 = 0.08 and 𝑤2 = 0.92 plans A and E are DEA efficient. For weights 𝑤1 = 0.24 and 
𝑤2 = 0.76, both plans D and E are DEA efficient. In fact, plans A, D and E are the only efficient 
plans in the example. For the others, plan N for example, its efficiency score is 0.979 (𝑤1 = 0.0 and 
𝑤2 = 1.00), 0.980 (𝑤1 = 0.08 and 𝑤2 = 0.92), 0.976 (𝑤1 = 0.24 and 𝑤2 = 0.76), and 0.920 
(𝑤1 = 1.0 and 𝑤2 = 0.0. Thus, the best weights for plan N are 𝑤1 = 0.08 and 𝑤2 = 0.92, and it 
obtains an efficiency score of 0.980 which is its best efficiency score calculated for its best weights. 
Without weight restrictions, the peer plans for plan N are A and E, where plan A is a slightly 
more important peer with a peer-weight of 0.54. DEA determines that the relative importance (or 
weight) put on rectal gEUD versus PTV dose max is 0.08 and 0.92 for plan N, respectively. Most 
other plans, with the exception of plan D, have similar optimal weights. Only plan D has the option to 
put all the weight on rectal gEUD. This result would indicate that four of the considered plans look 
most favourable when PTV dose max is considered and not when considering rectal gEUD, given that 
DEA is allowed to choose weights without restriction. This may be an undesired result as rectal gEUD 
is arguably the more important factor here. DEA allows us to add weight restrictions to control this, 
e.g. we could require that the DEA weight on rectal gEUD must be at least that of  the weight on PTV 
dose max, leading to a different, but more clinically desirable assessment of plan efficiency scores and 
targets. With the weight restriction, plan N now has optimal input weights of 𝑤1 = 0.50 (rectal 
gEUD) and 𝑤2 = 0.50 (PTV dose max), and a new target point N** in Figure 2. The choice of weight 
restrictions affects the target. If, for instance the weight of rectal gEUD is only required to be at least a 
fifth of the weight of PTV dose max, the target for N coincides with point E in Figure 2 (this is not 
shown in the figure). The introduction of weight restrictions also renders plans inefficient that were 
initially efficient, such as plan A which becomes inefficient in both cases. 
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Example 3: We now assume the same setting as in Example 1 with only two parameters to assess plan 
quality (rectal gEUD and PTV V95). Comparing plans as outlined in Example 1 is not entirely fair, as 
Example 1 disregards differences in patient geometry. When considering rectal gEUD, one factor that 
strongly affects this value is the patient-specific overlap between PTV and rectum, which is out of the 
radiotherapy planner’s control. In Figure 3 this overlap is indicated by the size of the circle where 
bigger means higher overlap. When assessing quality of plan N via DEA efficiency, it does not appear 
fair to compare plan N which has a relatively high overlap of 12.43% to A and D which both have 
lower overlap. Hence, the target determined for N in Example 1 may not be achievable.  
When performing DEA, one may want to take environmental factors into account. 
Environmental factors are factors that influence the performance of DMUs but are external to and out 
of the control of the DMUs. Patient anatomy or geometry is a treatment planning environmental factor 
since the relative positions of PTV and organs at risk clearly affect plan quality yet it cannot be 
influenced by the planning process. In the case of prostate radiotherapy planning, the percentage 
overlap of PTV and rectum is the dominant environmental factor. How to best account for patient 
geometry within the DEA process is discussed later. 
In summary, Example 1 is straightforward as it has a single input and output. Efficiency could 
have been determined as a simple normalised ratio of output over input. Likewise, Example 2 was 
used to illustrate the use of input and output weights in DEA.  Finally, Example 3 introduces the idea 
of environmental factors outside of a planner’s control. We further expand on all these ideas in the 
following. It is important to note that DEA can cope with any number of inputs and outputs in 
principle but its discriminatory ability can decline with increasing numbers of inputs and outputs 
especially with small data sets. DEA automatically determines the weights by solving an optimisation 
problem for each plan under investigation, thereby applying appropriate operations research 
techniques. It may be useful at this point to introduce the mathematical description of DEA using 
variable returns to scale. For more detailed descriptions the reader is referred to Charnes et al (1994).  
The DEA efficiency of plan 𝑘 from j=1. . . n plans is given by solving the following linear 
programme (model stated in multiplier form and variable returns to scale without consideration of 
weight restrictions or environmental variables): 
 
𝑀𝑎𝑥 ℎ𝑘 =  ∑ 𝑢𝑟
𝑠












 𝑦𝑟𝑗 − ∑ 𝑣𝑖
𝑚
𝑖=1
 𝑥𝑖𝑗  − 𝑢0 ≤ 0, (𝑗 = 1, . . . , 𝑛) 
 
𝑢𝑟 ≥ 0, (𝑟 = 1, … , 𝑠) 
 
𝑣𝑖 ≥ 0, (𝑖 = 1, … , 𝑚)  
 
Where: 
ℎ𝑗 is the relative efficiency of plan 𝑗 
𝑣𝑖 is the weight determined for input 𝑖; 
𝑚 is the number of inputs; 
𝑢𝑟 is the weight variable determined for output 𝑟;  
𝑢0 is a variable related to returns to scale; 
𝑠 is the number of outputs; 
𝑥𝑖𝑗 is the magnitude of the 𝑖-type input for plan 𝑗; 
𝑦𝑟𝑗 is the magnitude of the 𝑟-type output for plan 𝑗; 
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n  is the number of plans. 
Additional constraints can be added to the basic DEA model to ensure adequate consideration of 
environmental variables and weight restrictions. Several forms of weight restrictions can be included 
(see also Allen et al 1997). Here we apply a constraint to ensure that the ratio of weights of two 
inputs, 𝑖1 and 𝑖2, is at least 𝛼: 
𝑣𝑖1
𝑣𝑖2
≥ 𝛼 or equivalently 𝑣𝑖1 ≥ 𝛼𝑣𝑖2. In Example 2 we would choose 
𝛼 = 1. To capture the environmental factor in Example 3, it can be included as another output to the 
model since this ensures the comparison target is computed with at least the same overlap or the 
model can be modified to take environmental differences into account as explained below. 
 
In general, DEA can be conducted in an input orientation or an output orientation. In an input-oriented 
model, DEA searches for potential improvement of a DMU through proportional reduction of the 
inputs. Alternatively, in an output-oriented model, the potential improvement of a DMU is found by 
proportional augmentation of the outputs. As with our previous work we focus on input-oriented 
models which make sense in the context of treatment plan design since it is usual to optimise the plan 
to ensure that the PTV receives the prescribed dose after which potential reductions of dose to organs 
at risk are explored. An input oriented model provides the target doses, that is the minimum doses to 
OARs, which should be achievable by the treatment plan. 
 
2. Method 
This retrospective non-interventional study was subject to Institutional ethics approval. Forty one, 
78Gy IMRT prostate treatment plans were selected based only on a date range.  All plans were 
generated using an Eclipse treatment planning system V11 (Varian Medical Systems, Ca, USA) and 
all were clinically acceptable. The twin treatment planning requirements of PTV cover and 
minimisation of normal tissue dose was considered in the DEA plan evaluation. The metrics selected 
were PTV V95, the percentage of PTV volume receiving at least 95% of the prescribed dose and 
rectal generalised equivalent uniform dose (gEUD) with the volume effect parameter equal to 8 
(Niemierko 1997). In practical terms, the rectum is the only normal tissue structure that impacts 
prostate PTV cover and therefore the only normal tissue structure considered in this analysis. Other 
organs at risk can easily be accommodated by the DEA method, which is a strength of DEA. 
However, a greater number of inputs may result in a greater number of fully efficient plans. It is 
therefore sensible to limit the organs at risk to only those that most influence plan quality, especially 
when only a low number of plans is analysed. In treatment planning it is usual to constrain the 
maximum dose to the PTV; therefore a second input of PTV maximum is used. The key summary 
statistics for the plans used are; rectal gEUD mean 59.2 Gy (range 52.4-62.1 Gy), PTV-rectal overlap 
11.7% (5.5-18.1 %), PTV V95 98.2 % (95.1-99.9 %) and PTV dose max 82.0 Gy (80.2-84.5 Gy), 
shown in Figure 4. As with our previous work, an input orientated variable returns to scale approach 
was used. In order to determine the most suitable DEA model, it is necessary to understand how the 
handling of two parameters, patient geometry and DEA weights, can influence the outcome. 
The planning trade-off between dose to PTV and rectum is influenced by the patient geometry 
and in particular the overlapping volume of rectum and PTV. This may be considered an 
environmental factor in DEA terms and can be handled in one of three ways, as either a DEA output 
(as this ensures the DEA model targets have the same or worse environmental factor), by 
categorisation or by making an overlap-based adjustment to the rectal dose. The first approach would 
thus have two outputs, PTV V95 and the overlap, and two inputs gEUD (Gy) and PTV dose max (Gy) 
(models M1 and M4 in Table 3). Since we have assumed an input orientation and variable returns to 
scale, these models identify the minimum level of input associated with the respective levels of 
output. Thus the DEA model would ensure that plans with high (or low) levels of overlap output are 
only compared with target plans with equal or greater levels of overlap. The second approach, 
categorisation (Banker and Morey, 1986), uses the amount of overlap to construct an ordinal ranking 
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of plans from low to high overlap so that high overlap plans are only compared with similar plans 
whereas low overlap plans are compared with all other plans including higher levels of overlap (M2 
and M5 in Table 3). The third approach adjusts the rectal dose taking overlap into consideration using 
a three stage process comprising firstly a DEA analysis without considering overlap, secondly 
construction of a different frontier of radial slack from the first stage to identify the minimum amount 
of slack due to overlap, and thirdly rerunning a DEA analysis but with the inputs adjusted for this 
minimum amount of slack due to overlap (M3 and M6). 
To evaluate the influence of DEA weights, the three approaches just cited were repeated with 
the addition of relative DEA input weight restrictions to ensure that the rectal dose is appropriately 
prioritised over the PTV dose max. In the repeat models we constrained the ratio of rectal dose to 
PTV dose max DEA input weighting to be ≥10. This value was chosen based on its ability to identify 
potential rectal dose improvements at a level of clinical significance as discussed later.  Table 3 shows 
the attributes of the six models.    
Model names indicate model setup, as explained in this paragraph: E stands for environmental, 
with options output (O), categorical (C) and adjusted (A), and W for weight restrictions with options 
yes (Y) and no (N). In models M1: EO_WN and M4: EO_WY the percentage of PTV overlapping the 
rectum is considered as a second DEA output. In models M2: EC_WN and M5: EC_WY the overlap 
is considered by placing a plan in one of three categories according to degree of overlap. A plan is 
then only compared to plans with the same or higher overlap category. In models M3: EA_WN and 
M6: EA_WY the DEA target values are adjusted according to the observed limiting influence of 
overlap as explained in the next paragraph. In models M1: EO_WN, T2: EC_WN and M3: EA_WN, 
DEA was performed without constraining the input weights, whilst in models M4: EO_WY, M5: 
EC_WY and M6: EA_WY, the relative input weights were constrained.  
In DEA, radial slack is a measure of the inefficiency of production, in an economical 
interpretation, and in our application is the extent to which it might be possible to reduce doses to the 
organ at risk (rectum). Radial slack can be considered to be comprised of two components, that due to 
patient geometry (PTV-rectal overlap) and that due to plan quality. To evaluate radial slack we first 
perform DEA on the dataset without considering overlap. Second, the resultant radial slack for each 
plan is plotted against its overlap from which a frontier is determined by a linear fit of points on the 
Pareto efficient frontier. The frontier effectively describes the minimum amount of radial slack 
attributable to overlap. With reference to Figure 5, two plans with a similar PTV-rectal overlap of 
approximately 12.7% are highlighted. One lies on the overlap frontier with a radial slack value of 2.3 
Gy, wholly attributable to overlap. The other has a total radial slack of 8.1 Gy of which 8.1 - 2.3 = 5.8 
Gy is therefore attributable to plan quality.  Since the overlap component of radial slack cannot be 
influenced by the planning process, for each plan this is subtracted from the rectal gEUD to yield the 
planning component of radial slack. We can refer to this as the adjusted rectal gEUD. To calculate 
DEA efficiency, rectal gEUD is replaced with the adjusted rectal gEUD without the requirement to 
further consider overlap.    
The Spearman rank order correlation was used to compare the results of each model to assess if 
the ranking order was affected by the trial method (SigmaPlot 13.0, Systat Software Inc. CA).  A 
comparison of plans appearing within the upper and lower quartiles of efficiency score for each model 
was also undertaken to evaluate inter-model consistency. An in-house software package pyDEA 
(Raith et al.2012) was used to perform the DEA analysis. 
 
3. Results 
The calculated efficiency score and range of efficiency scores is dependent upon the DEA model used 
and is shown in Figure 6. The greatest range was observed when the environmental factor is 
incorporated into the adjusted rectal dose (M6:EA_WY). This is in part due to the much reduced scale 
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of the rectal dose input data. This is not seen in its non-weight constrained version (M3:EA_WN) 
because the dominant input in this model is the maximum dose to PTV (PTV dose max). The other 
two weight constrained models (M4:EO_WY and M5:EC_WY) displayed a greater range of 
efficiency scores than any of the unconstrained models due to the increased significance of the rectal 
dose over PTV dose maximum. Of greater importance than the range of efficiency scores, however, is 
the ability of the DEA model to identify the plans that constitute the efficient frontier and those which 
can significantly improve. Thus the ranking order of plans is a more important consideration than the 
efficiency range. The Spearman rank order correlation indicates that there is a positive correlation 
between the relative rank of individual plans obtained by any of the models compared to any other 
and that the relationship is statistically significant (P<0.05) (Table 3). There is a strong association 
between the three unrestricted weight models M1:EO_WN, M2:EC_WN and M3:EC_WN and also 
between the three restricted weight models M4:EO_WY, M5:EC_WY and M6:EA_WY but a weak 
association between restricted and unrestricted weight models.  
The number of fully efficient plans ranged from four to nine dependent on the model and three 
plans were rated fully efficient by all six models. There was a difference in the identification of the 
most inefficient plans between the three models not using weight restrictions and the three models 
using weighting restrictions. In both cases, seven plans were determined to lie within the lowest 
efficiency quartile irrespective of which of the three variants was used. However of those seven plans, 
only two were common to both the groups without weight restriction and with weight restriction.  
Four plans were ranked in either the upper and lower quartiles dependant on the DEA model. Two of 
these plans were assessed as maximally efficient when no weight restrictions were used though 
possible rectal improvements were identified with the addition of weight restrictions.     
Target doses for rectum and PTV dose max were influenced by the addition of the relative DEA 
weight restriction. Without DEA weight restrictions, the mean (standard deviation) of identified 
possible reduction to rectal gEUD and PTV maximum doses was 0.86 (0.73) and 1.12 (0.90) Gy 
respectively. With the introduction of the weight restriction the identified possible reduction to rectal 
gEUD and PTV maximum doses was 3.13 (2.20) and 0.98 (0.97) Gy respectively. Thus the addition 
of weight restrictions allowed for the identification of significant potential rectal improvements at the 
expense of a small reduction in PTV maximum identification as shown in Figure 7. 
 
4. Discussion 
The strength of DEA lies in a minimal number of assumptions regarding the relationships between the 
inputs and outputs and estimation of DEA weights, which can indicate the relative importance of 
different parameters when it comes to DEA performance. It is important, however, that the DEA 
method chosen reflects the most important treatment planning priorities. In other words, it would not 
be helpful if the efficiency ranking was sensitive to clinically insignificant differences in plan quality. 
For example, it would be undesirable for a plan to be identified as DEA efficient due to having a 
small PTV dose maximum when the rectal dose could be significantly further reduced, as was the case 
for some plans here when using unrestricted DEA weights. With our data it was found that restricting 
the allowable ratio of rectal gEUD to PTV maximum weighting we could limit the influence of 
relatively small differences in PTV maximum whilst providing a suitable emphasis on clinically 
significant rectal dose reduction. To validate this choice of weight restriction differing weight limits 
were applied to one of the models (model M4: EO_WY that treated overlap as an output) to assess the 
effect on rectal and PTV maximum dose targets. Weight limits used for the ratio of weights were: 
none, ≥ 0.2, ≥ 0.5, ≥ 1 and ≥ 10. It was found that the choice of weight limit did not affect the target 
doses provided that it was ≥ 0.5 as shown in Figure 8. The probability of rectal toxicity increases by 
the order of 1% per Gy increase in rectal gEUD at this dose level (Tucker et al., 2012) and hence to be 
clinically useful the DEA method needs to be sensitive enough to identify those plans where 
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improvements to rectal gEUD greater than several Gy are possible. Figure 7 shows box plots of 
identified potential dose reductions to rectum and PTV maximum for each of the six models. This 
demonstrates that unless appropriate weight restrictions are used as in models M4:EO_WY, 
M5:EC_WY and M6:EA_WY, the DEA model with two inputs is unable to identify plans for which 
significant rectal dose reduction is possible. It also demonstrates that the cost of using weight 
restrictions is small in terms of potential reduction to the PTV maximum doses though it is observed 
that there is a target dose reduction for all models with smaller dispersion of doses. It is clear therefore 
that a weight restriction is required to ensure clinical relevance when multiple DEA inputs are used 
and further research is required to determine the best choice of weight restrictions for differing organs 
at risk under consideration.  
How to handle the environmental factor (geometric descriptor) is considered by way of three 
possible approaches; by considering rectal-PTV overlap as an output, by categorisation (i.e. placing 
the plans into a number of bins dependent on their overlap) or by adjusting the rectal target dose based 
on overlap. All three models have a strong statistical association. However, categorisation suffers 
from the somewhat arbitrary choice of category boundary and the fact that at each category boundary 
a plan could be fully efficient simply because it is at the boundary. Hence it is possible that a plan that 
could be significantly improved would not be identified using a categorical approach. Of the other 
two models, the plan ranking is shown to be very similar as shown in Figure 9, though treating the 
overlap as an output has the advantage of requiring less data manipulation.  Notwithstanding, the 
adjusted dose method identifies the amount of radial slack (reduction in gEUD) attributable to the 
amount of overlap which potentially could stimulate better understanding of the relationship between 
these two variables in further efficiency studies. 
 
5. Conclusion 
The input oriented DEA method is the method of choice when performing plan analysis using the key 
undesirable plan metrics as the DEA inputs. When considering multiple inputs, it is necessary to 
constrain the DEA input weights in order to identify potential plan improvements at a level of clinical 
significance. In this case we wished to identify rectal dose improvements of greater than 2 Gy which 
was only possible using a relative rectal to PTV maximum DEA input weight restriction of at least 
greater than 0.5. There appears to be no clear advantage for any given approach for the handling of 
the geometric consideration PTV-rectal overlap; though the categorisation method is somewhat 
arbitrary. 
The flexibility of DEA in modelling the appraisal of plans has been demonstrated in this paper 
as has been the ability to incorporate clinical knowledge and expectations into the analysis. The use of 
DEA to identify plans that are best practice to form an ongoing benchmark reference set provides a 
new framework for clinicians and researchers alike. Over time, one might expect this reference set to 
change as new technologies and thinking emerge and an obvious question is whether the frontier is 
moving outwards and at what rate.  
 
Due to the sensitive nature of the data, we are not in a position to share data as we do not have 
permission to do so. 
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